Do We Get Samples of the Report?

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

How to Buy a Market Report?

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

In Which Format Will I Get the Report?

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

In How Much Time I will Get the Report After Purchase?

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

How Can I Get the Report Customized?

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

How Much Will It Cost to Get a Report Customized?

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

Can I Buy Only a Particular Segment of the Study?

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Is There Any Available Discount?

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

Which Services Are Complimentary Before Purchasing the Report?

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Will I Receive a Bill or Invoice for the Report Purchased?

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

What If I am Unable to Find the Report in the Catalog?

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

How Often Are the Existing Studies Updated?

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

What If the Report Does Not Contain the Information I Want?

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Is the Payment Refundable?

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

What If the Payment Fails?

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Can I Avail the Report of a Particular Country/Region?

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Do You Offer Support After Purchase?

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2017

DESCRIPTION

TABLE OF CONTENTS

RELATED REPORTS

SAMPLE REQUEST

REVIEWS

DESCRIPTION

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape.

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation and chemotherapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 27, 30, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 4, 7 and 3 molecules, respectively.

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

TABLE OF CONTENTS

Introduction 6
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview 7
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Development 8
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment3
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development 37
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drug Profiles 67
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects 492
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products 497
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones 498
Appendix 512

List Of Tables

List of Tables
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H2 2017 19
Number of Products under Development by Companies, H2 2017 21
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 22
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 23
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 24
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 25
Number of Products under Development by Universities/Institutes, H2 2017 26
Products under Development by Companies, H2 2017 28
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 29
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 30
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 31
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 32
Products under Development by Universities/Institutes, H2 2017 33
Number of Products by Stage and Target, H2 2017 35
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 36
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 37
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 38
Number of Products by Stage and Mechanism of Action, H2 2017 40
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 41
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 42
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 43
Number of Products by Stage and Route of Administration, H2 2017 45
Number of Products by Stage and Molecule Type, H2 2017 47
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AbbVie Inc, H2 2017 48
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Altor BioScience Corp, H2 2017 49
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by arGEN-X BV, H2 2017 49
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H2 2017 50
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Array BioPharma Inc, H2 2017 50
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017 50
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H2 2017 51
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AstraZeneca Plc, H2 2017 51
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Atara Biotherapeutics Inc, H2 2017 52
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bio-Path Holdings Inc, H2 2017 52
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioLineRx Ltd, H2 2017 53
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioSight Ltd, H2 2017 53
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Boston Biomedical Inc, H2 2017 53
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bristol-Myers Squibb Co, H2 2017 54
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cantargia AB, H2 2017 54
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celgene Corp, H2 2017 55
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cellectis SA, H2 2017 56
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cielo Therapeutics Inc, H2 2017 56
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Daiichi Sankyo Co Ltd, H2 2017 56
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2017 57
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Eisai Co Ltd, H2 2017 57
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Epizyme Inc, H2 2017 58
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Galena Biopharma Inc, H2 2017 58
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Gamida Cell Ltd, H2 2017 59
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlaxoSmithKline Plc, H2 2017 59
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlycoMimetics Inc, H2 2017 60
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GT Biopharma Inc, H2 2017 60
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hovione FarmaCiencia SA, H2 2017 60
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hybrigenics SA, H2 2017 61
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by IGF Oncology LLC, H2 2017 61
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ilyang Pharmaceutical Co Ltd, H2 2017 62
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Immune Pharmaceuticals Inc, H2 2017 62
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Incyte Corp, H2 2017 63
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Johnson & Johnson, H2 2017 63
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Juno Therapeutics Inc, H2 2017 64
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by JW Pharmaceutical Corp, H2 2017 64
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Karyopharm Therapeutics Inc, H2 2017 65
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by LG Chem Ltd, H2 2017 65
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017 66
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 66
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Natco Pharma Ltd, H2 2017 67
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Novartis AG, H2 2017 68
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by OncoTherapy Science Inc, H2 2017 68
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 69
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pfizer Inc, H2 2017 69
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pharma Mar SA, H2 2017 70
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by PharmaEssentia Corp, H2 2017 70
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Phylogica Ltd, H2 2017 71
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Sellas Life Sciences Group Ltd, H2 2017 71
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Selvita SA, H2 2017 72
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Shenogen Pharma Group Ltd, H2 2017 72
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by SignalChem Lifesciences Corp, H2 2017 72
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Stemline Therapeutics Inc, H2 2017 73
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 74
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Synactix Pharmaceuticals Inc, H2 2017 74
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Syndax Pharmaceuticals Inc, H2 2017 75
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017 75
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by TRACON Pharmaceuticals Inc, H2 2017 76
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Xencor Inc, H2 2017 76
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Xspray Pharma AB, H2 2017 77
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H2 2017 503
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H2 2017 (Contd..1), H2 2017 504
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H2 2017 (Contd..2), H2 2017 505
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H2 2017 (Contd..3), H2 2017 506
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H2 2017 (Contd..4), H2 2017 507
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, H2 2017 508

RELATED REPORTS

COVID-19 Outbreak-Global Chronic Kidney Disease (CKD) Drugs Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

Chronic kidney disease (CKD) means your kidneys are damaged and cant filter blood the way they should. The main risk factors for developing kidney disease are diabetes, high blood pressure,

USD 3660 View Report

COVID-19 Outbreak-Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease which includes emphysema, chronic bronchitis, refractory asthma, and some forms of bronchiectasis. This disease is characterized by increasing breathlessness, wheezing,

USD 3660 View Report

SAMPLE REQUEST

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

REVIEWS

There is no Reviews available

Search and Get the Latest Market Research Reports

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2017

COVID-19 Outbreak-Global Chronic Kidney Disease (CKD) Drugs Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

COVID-19 Outbreak-Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

FAQs